Introduction
============

Long-term prescription of benzodiazepines has significant negative outcomes, causing significant costs to healthcare and wider society; however, many physicians continue to prescribe these and patients wishing to withdraw rarely receive advice or support ^[@ref-1]^. The prevalence of long-term benzodiazepine use in Europe ^[@ref-2],\ [@ref-3]^ remains high despite policy recommendations to limit their use ^[@ref-4]--\ [@ref-7]^.

In Spain, long-term use is extensive, with more than 7% of the population using them regularly ^[@ref-8],\ [@ref-9]^, whereas in the United Kingdom, Germany or Netherlands (where policies aim to restrict use), prevalence of their use is less than 2% ^[@ref-2],\ [@ref-3]^. Based on the cost of long-term benzodiazepine prescription alone, we estimate the cost in Spain is over €70 million per annum and, if the consequences of associated morbidities were considered, the full economic cost to healthcare is much higher ^[@ref-10]^.

Evidence suggests that long-term use has a lack of clinical benefits ^[@ref-11]^, and guidelines clearly recommend prescribing on a short-term basis. Given the implications associated with longer-term use, several programs designed to taper off the use of benzodiazepines have been developed, which have been demonstrated to be effective and safe ^[@ref-12],\ [@ref-13]^. However the uptake and use of such interventions is not widespread. A case for the use of such interventions could be supported by robust evidence of cost effectiveness to show that this was an efficient use of finite healthcare resources. To our knowledge there are no full economic evaluations in this area. Economic evidence on benzodiazepine cessation programs report predominantly how costs vary by level of complexity, as studies have tended to report the absolute costs of programs (as opposed to the incremental cost over Treatment as Usual (TAU)). Full economic evaluations are therefore required ^[@ref-14],\ [@ref-15]^.

A clinical trial in primary care has already been reported, which assesses the effectiveness of two interventions to discontinue long-term benzodiazepine use. The two programs evaluated were found to be more effective than usual care in stopping long-term benzodiazepine use in patients without severe co-morbidity ^[@ref-16]^. Having established that both programs are clinically effective in reducing long-term use, the question then arises as to whether they are also cost-effective.

To our knowledge, this is the first cost-effectiveness analysis of benzodiazepine cessation programs in Spain. To inform policy, we simultaneously examine generic health gains (expressed in Quality-Adjusted Life Years (QALYs)) ^[@ref-17],\ [@ref-18]^ and associated costs to healthcare; this aims to inform the decision-makers by comparing the Incremental Cost Effectiveness Ratio (ICER) against willingness-to-pay threshold ^[@ref-19]--\ [@ref-21]^. The clinical trial assessed the effectiveness of two interventions in primary care using 'discontinuation of benzodiazepine use' as the primary outcome. The economic evaluation adopted the perspective of the Spanish Health system and Spanish unit costs were applied to the cost of general practitioner (GP) training, per-protocol cost of GP intervention, costs of follow up visit and the cost associated with benzodiazepine use.

Methods
=======

Participants and interventions
------------------------------

The clinical trial has been described by Vicens *et al.* (2014) ^[@ref-16]^. Briefly, a three-arm, parallel, multicentre, cluster-randomised trial was carried out in Spain, which aimed to compare the effectiveness of two brief structured, tapering interventions delivered by the GP, to discontinue long-term benzodiazepine use versus a control group that received TAU. The current study presents the economic analysis conducted alongside this randomised controlled trial from a health systems perspective.

The interventions included a structured educational interview with gradual dose reduction either (i) with follow-up visits (Structured Interview with Follow-up - SIF) or (ii) with written instructions (Structured Interview without Follow-up - SIW) instead of a follow-up visit. The initial interventions' visit in both groups lasted about 20 minutes; SIF arm patients scheduled 12 minutes follow-up appointments every 2--3 weeks until the end of the dose reduction and each appointment had reinforced education, reassured patients regarding withdrawal symptoms and obtained patient agreement for the next step in dose reduction. The patients in the SIW group received written instructions reinforcing educational information at their first and only contact with their GP, along with a tailored gradual dose-reduction until benzodiazepine cessation.

GPs from 21 primary care centres in the three regions of Spain were enrolled and, in total, 75 GPs were randomised to one of the three arms (TAU, SIW, SIF). Patients eligible for the trial were aged 18 to 80 years and had been taking benzodiazepines daily for at least 6 months and did not have a severe mental or physical illness. GPs were randomised once the patients were included, and GPs from the intervention groups were scheduled to a two-hour training session in benzodiazepine withdrawal. GPs of the SIF arm received an additional 30 minutes training in how to proceed in the follow-up visits. Because each GP treated several patients, the GP time cost was spread across patients seen by the GP during this study.

Resource use and associated unit costs
--------------------------------------

Evidence in the literature would suggest that long-term benzodiazepine use may have negative health consequences that would have cost consequences to health service. However, we restrict our consideration of cost to consider whether the health gains within the trial period justify the cost of the cessation programs plus subsequent benzodiazepine use.

The costs of the cessation programs include GP training and subsequent patient follow-ups, if any, with the GP for benzodiazepine discontinuation. The cost of the training programs per GP was calculated. The training programs were run in three regions as group GP-delivered workshops and the required resources were considered to calculate the program cost (includes cost of training, trainers' time, travel and accommodation and all other overhead costs).

Patient resource use (both in terms of training time and follow-up visits) were multiplied by the unit cost of a GP visit to obtain total GP cost. The unit cost of GP visit can vary across Spanish regions and are published in official regional bulletin by each region ^[@ref-22]--\ [@ref-24]^. The cost associated with training GPs in SIF and SIW were based on the trainer time (in all cases trainers were GPs, so an hourly rate of €75 per hour was used), travel and accommodation costs by regions where training was provided, and cost associated with administration to organise and provide the workshops.

In Spain, benzodiazepine prescribing is regulated and only formulations with a reference price (published authorised by the Spanish Agency of Drugs and Sanitary products (AEMPS)) are available. The nomenclature web application of the AEMPS ^[@ref-25]^ was used to obtain benzodiazepines cost for this price year. Retrospective levels of benzodiazepine use by participants in the randomised control trial was assessed at baseline, 6 month and 12 months; these consumption patterns were reviewed and confirmed by prescription claims in the clinical records.

Costs are presented in Euros (€) for the price year 2013 and for international comparison, equivalent costs are presented in Pound Sterling (GBP) and US Dollar (USD). Since the follow-up period lasted 1 year, no extrapolation over time was executed, discounting was not necessary. Analysis was conducted using Stata 13.

Outcomes: mapping generic health state utilities from condition specific measure
--------------------------------------------------------------------------------

As the original trial does not include a measure of individuals' generic health-state (e.g. EQ-5D), to provide outcomes that have broad policy-relevant application (e.g. QALYs), we evaluated several mapping functions to allow cross walking of a condition-specific measure to obtain a utility score. Specifically, Hospital Anxiety and Depression Scale (HADS) scores were available in the clinical trial, which were used to estimate generic health utility outcomes.

To identify an up-to-date and appropriate method to map clinical trial outcomes onto equivalent generic health states, *HERC Database of Mapping Studies* (Version 3.0 - June 2014) was searched ^[@ref-26]^. Within this resource, we identified that Brazier *et al* (2014) ^[@ref-27]^ systematically reviewed studies with estimation of mapping functions in mentally ill populations. Specifically, the authors critically appraised two studies mapping HADS to generic preference-based measures of health and based on their appraisal, and after comparing post-estimation statistics from each study, we selected to utilise the regression analysis of EQ-5D and HADS ^[@ref-28]^. The mapping algorithm utilises the specific scores from the two subscales for depression (HADS-D) and anxiety (HADS-A) to estimate EQ5D index. The results provide individual utility at each time point, and by applying an area under the curve approach these utility values were used to estimate QALYs ^[@ref-29]^.

Cost effectiveness analysis
---------------------------

Unadjusted Incremental Cost Effectiveness Ratio (ICER) for each intervention group (SIW and SIF) are calculated against TAU using the following formula: $$ICER = \frac{{\overline{C}}_{I} - {\overline{C}}_{T}}{{\overline{E}}_{I} - {\overline{E}}_{T}}$$ where C is the costs and E is the effects (as QALYs) in the Intervention (I) or TAU(T).

To estimate the joint distributions of cost and QALYs, non-parametric bootstrapping was conducted on the observed data ^[@ref-30]^. Conventionally, the results of the bootstrap are presented as a scatter plot on the cost effectiveness plan ^[@ref-31]^; however, to jointly present confidence interval around costs and outcomes a confidence ellipse is generated. This jointly indicates the incremental costs and QALYs on the 50%, 75% and 95% confidence intervals, indicating in the CE plane the probability space within which we are confident the true ICER is found.

To evaluate cost-effectiveness of our estimates against willingness-to-pay threshold of a health system decision maker, a range of maximum monetary values were used. To present how the probability of interventions being cost effect increases as decision makers willingness-to-pay increases, a cost effectiveness acceptability curve (CEAC) is generated ^[@ref-21]^.

Ethical approval
----------------

Our study protocol has been approved by the Primary Care Research Committee and the Mallorca Ethical Committee of Clinical Research (IB 1146/09 PI).

Results
=======

At 12 months, data were available from 523/532 (98.3%) patients. The two structured educational interview programs were found to be more effective than usual care in stopping long-term benzodiazepine use over a 12-month period. The relative risks for benzodiazepine discontinuation were 3.01 (95% CI: 2.03 to 4.46) in the SIW and 3.00 (95% CI: 2.04 to 4.40) in the SIF group compared to usual care.

Unit cost, resource use and cost estimation
-------------------------------------------

[Table 1](#T1){ref-type="table"} presents unit costs associated with benzodiazepine use and, as healthcare costs vary in Spanish regions, region-specific costs utilised to provide the GP cessation program are given within the three study regions.

###### Unit costs associated with benzodiazepine use and cessation

  ----------------------------------------------------------------------------------------------------------------
                                                                   Quantity   Cost (€)   Unit        Reference
  ---------------------------------------------------------------- ---------- ---------- ----------- -------------
  **Initial GP visit (by region)**                                                                   

  Balearic Islands                                                 1          62         Per visit   BIOB 2012

  Catalunya                                                        1          40         Per visit   DOGC 2012

  Valencia                                                         1          56.39      Per visit   DOGV 2005

  **Follow-up visit (by region)**                                                                    

  Balearic Islands                                                 1          32         Per visit   BIOB 2012

  Catalunya                                                        1          40         Per visit   DOGC 2012

  Valencia                                                         1          28.76      Per visit   DOGV 2005

  **Prescribed benzodiazepines ^[\*](#Tfn1){ref-type="other"}^**                                     

  Alprazolam 0.5                                                   0.50 mg    2.1        Per month   MSSSI 2014

  Diazepam 5                                                       5 mg       1.9        Per month   MSSSI 2014

  Lormetazepam                                                     1 mg       2          Per month   MSSSI 2014

  Lorazepam                                                        1 mg       1.7        Per month   MSSSI 2014

  Zolpidem                                                         10 mg      2.8        Per month   MSSSI 2014

  Other benzodiazepine                                             \-         1.81       Per month   MSSSI 2014\
                                                                                                     (Estimated)
  ----------------------------------------------------------------------------------------------------------------

^\*^Costs presented here of the commonly prescribed benzodiazepines are the weighted average. However, in the individual-level cost-analysis the specific costs per dose formulation is used

To estimate the costs and cost consequences of implementing the cessation program, mean estimates of the use of healthcare resources associated with benzodiazepine use and cessation are calculated (see [Table 2](#T2){ref-type="table"}). This indicates the average number of GPs that attended training workshops per region and study group, the number of initial visits GPs provide to long-term users of benzodiazepines, and mean reported contact following initial visit. To indicate the consequence to the health care system, [Table 2](#T2){ref-type="table"} indicates the proportion of study sample consuming specific benzodiazepine at initial visit, then at 6- and 12-month follow-up.

###### Mean use of healthcare resources associated with benzodiazepine use and cessation

  Categories of resource use                                                                            SIW     SIF   TAU                   
  ----------------------------------------------------------------------------------------------------- ------- ----- ------- ----- ------- -----
  **GP attendance per workshop (N) ^[\*](#Tfn2){ref-type="other"}^**                                                                        
  Balearic Islands                                                                                      3       3     3       3     3       3
  Catalunya                                                                                             4.5     2     4       2     5.5     2
  Valencia                                                                                              2       3     3       3     1.7     3
  **Initial visit to the GP for Benzodiazepines Cessation Program ^[\*\*](#Tfn3){ref-type="other"}^**                                       
  Balearic Islands                                                                                      1       61    1       64    0       62
  Catalunya                                                                                             1       60    1       56    0       76
  Valencia                                                                                              1       47    1       71    0       35
  **Contact visits to the GP**                                                                                                              
  Balearic Islands                                                                                      3.298   57    6.651   63    3.576   59
  Catalunya                                                                                             2.424   59    4.727   55    2.135   74
  Valencia                                                                                              4.022   45    8.103   68    2.471   34
  **Proportion of sample consuming specific benzodiazepine (over time):**                                                                   
       **Baseline**                                                                                                                         
  Alprazolam                                                                                            0.179   168   0.199   191   0.150   173
  Diazepam                                                                                              0.089   168   0.115   191   0.052   173
  Lorazepam                                                                                             0.304   168   0.346   191   0.312   173
  Lormetazepam                                                                                          0.149   168   0.099   191   0.214   173
  Zolpidem                                                                                              0.119   168   0.147   191   0.150   173
  Other Benzodiazepine ^[\*\*\*](#Tfn3){ref-type="other"}^                                              0.250   168   0.168   191   0.208   173
       **6 months**                                                                                                                         
  No benzodiazepine                                                                                     0.459   157   0.382   186   0.146   171
  Alprazolam                                                                                            0.096   157   0.113   186   0.140   171
  Diazepam                                                                                              0.096   157   0.177   186   0.070   171
  Lorazepam                                                                                             0.134   157   0.108   186   0.135   171
  Lormetazepam                                                                                          0.064   157   0.081   186   0.216   171
  Zolpidem                                                                                              0.076   157   0.065   186   0.117   171
  Other Benzodiazepine ^[\*\*\*](#Tfn4){ref-type="other"}^                                              0.134   157   0.118   186   0.263   171
       **12 months**                                                                                                                        
  No benzodiazepine                                                                                     0.452   168   0.450   191   0.150   173
  Alprazolam                                                                                            0.101   168   0.105   191   0.145   173
  Diazepam                                                                                              0.077   168   0.126   191   0.087   173
  Lorazepam                                                                                             0.149   168   0.188   191   0.243   173
  Lormetazepam                                                                                          0.077   168   0.073   191   0.197   173
  Zolpidem                                                                                              0.077   168   0.042   191   0.098   173
  Other Benzodiazepine ^[\*\*\*](#Tfn4){ref-type="other"}^                                              0.119   168   0.126   191   0.277   173

^\*^See *Extended data* ^[@ref-32],\ [@ref-33]^

^\*\*^Mean initial visit to GP are informed by the 'per-protocol' approach in that each treatment group specified the incremental GP visit required to provide specific benzodiazepine cessation program

^\*\*\*^Given the wide array of benzodiazepines available, this resource use table only reports specific formulations with market share above 5%

Applying unit cost to resource use, [Table 3](#T3){ref-type="table"} estimates mean costs associated with the healthcare resources that are required to provide the cessation program and the change in the cost of benzodiazepine in each group (no further extrapolation of cost-consequences beyond cost of benzodiazepine was done). Based on the available information, the mean total cost per patient over a 12 month period was €201.05 for SIW, €301.51 for SIF and €83.11 for TAU ^[a](#FN1){ref-type="other"}^.

###### Mean costs of healthcare resources associated with benzodiazepine use and cessation

  Categories of resource use                              SIW      SIF   TAU                     
  ------------------------------------------------------- -------- ----- -------- ----- -------- -----
  **Cost per GP workshop (€)**                                                                   
  Balearic Islands                                        468      3     543      3     0.00     3
  Catalunya                                               466      2     541      2     0.00     2
  Valencia                                                462      3     543      3     0.00     3
  **Cost of initial visit to the GP by participant**                                             
  Balearic Islands                                        62.00    61    62.00    64    0.00     62
  Catalunya                                               40.00    60    40.00    56    0.00     76
  Valencia                                                56.39    47    56.39    71    0.00     35
  **Cost of follow up visits to the GP by participant**                                          
  Balearic Islands                                        105.54   57    212.83   63    114.44   59
  Catalunya                                               96.95    59    189.09   55    85.41    74
  Valencia                                                160.89   45    324.12   68    98.82    34
  **Cost of benzodiazepine consumed (over time):**                                               
       **Baseline**                                                                              
  Alprazolam                                              4.50     168   5.01     191   3.79     173
  Diazepam                                                2.04     168   2.63     191   1.19     173
  Lormetazepam                                            7.29     168   8.29     191   7.49     173
  Lorazepam                                               3.04     168   2.03     191   4.36     173
  Zolpidem                                                4.00     168   4.93     191   5.05     173
  Other Benzodiazepine ^[\*](#Tfn5){ref-type="other"}^    5.42     168   3.63     191   4.51     173
       **6 months**                                                                              
  Alprazolam                                              2.41     157   2.85     186   3.54     171
  Diazepam                                                2.18     157   4.05     186   1.60     171
  Lormetazepam                                            3.21     157   2.58     186   3.23     171
  Lorazepam                                               1.30     157   1.65     186   4.41     171
  Zolpidem                                                2.57     157   2.17     186   3.93     171
  Other Benzodiazepine ^[\*](#Tfn5){ref-type="other"}^    2.90     157   2.56     186   5.71     171
       **12 months**                                                                             
  Alprazolam                                              2.55     168   2.64     191   3.64     173
  Diazepam                                                1.76     168   2.86     191   1.98     173
  Lormetazepam                                            3.57     168   4.52     191   5.83     173
  Lorazepam                                               1.58     168   1.50     191   4.01     173
  Zolpidem                                                2.60     168   1.41     191   3.30     173
  Other Benzodiazepine ^[\*](#Tfn5){ref-type="other"}^    2.58     168   2.72     191   6.02     173
  Total Cost per Average Patient                          201.05   149   301.51   173   83.11    152

^\*^Total cost only reports specific formulations (over 5% market share) however in analysis specific unit cost applied (Full list of unit cost available on request from the author (see annex)).

Health-state utility estimation
-------------------------------

Individual HADS scores were used to estimate health-state utility values at each time point. [Table 4](#T4){ref-type="table"} presents the unadjusted utilities by treatment group and time point. Applying area-under-the-curve approach and specifying accurate individual time intervals, unadjusted annual QALYs are estimated (see [Table 5](#T5){ref-type="table"}).

###### Unadjusted utilities by treatment group and time.

  Treatment group     Mean    (s.d.)   Median   Min     Max     N
  ------------------- ------- -------- -------- ------- ------- -----
  **SIW**                                                       
  Baseline utility    0.749   0.165    0.775    0.257   1.000   160
  6 months utility    0.795   0.152    0.826    0.346   1.000   159
  12 months utility   0.817   0.174    0.875    0.224   1.000   155
  **SIF**                                                       
  Baseline utility    0.731   0.154    0.744    0.273   1.000   184
  6 months utility    0.799   0.156    0.834    0.289   1.000   186
  12 months utility   0.811   0.166    0.850    0.173   1.000   178
  **TAU**                                                       
  Baseline utility    0.758   0.158    0.773    0.338   1.000   168
  6 months utility    0.784   0.152    0.816    0.346   1.000   171
  12 months utility   0.804   0.163    0.834    0.349   1.000   160

###### Unadjusted annual QALYs.

  Treatment group   Mean     (s.d.)   Median   Min       Max      N
  ----------------- -------- -------- -------- --------- -------- -----
  SIW               0.8681   0.2014   0.8819   -0.1066   1.6142   145
  SIF               0.8693   0.1804   0.8870   0.3222    1.3249   169
  TAU               0.8622   0.1756   0.8707   0.3694    1.1945   149

To control for individual-level variation in baseline utility and to estimate incremental QALYs for the intervention groups, ordinary least squares regression was used with baseline utility included as a covariate ( [Table 6](#T6){ref-type="table"} presents the regression outputs). The findings suggest that overall the model explains 56.06% of the variance in QALYs, that baseline utility is a significant predictor of change in QALYs, and the incremental QALY for SIW is 0.0144 (p=0.314) and for SIF is 0.0340 (p=0.014).

###### Regression analysis QALY controlling for baseline utility, treatment group.

  QALY               Coefficient   Std. Err.           P\>t    \[95% Confidence Interval\]   
  ------------------ ------------- ----------- ------- ------- ----------------------------- -------
  Baseline utility   .8658         .0356       24.30   0.000   .796                          .9357
  SIW                .0144         .0143       1.01    0.314   -.0137                        .0425
  SIF                .0340         .0138       2.46    0.014   .0069                         .0612
  Constant           .2020         .0290       6.97    0.000   .1453                         .2588

n= 463 R ^2^ = 0.5606

Incremental cost effectiveness analysis
---------------------------------------

The regression outputs suggest that baseline utility is a significant predictor overall QALY, so the adjusted coefficients are utilised to calculate point estimate of ICER. This indicates that the ICER for SIW is €8190.28/QALY and for SIF is €6423.53/QALY. However, examining 95% confidence intervals and statistical significance of the regression coefficients for SIW and SIF indicates a degree of uncertainty of the estimated health gain. To further explore the uncertainty surrounding the point estimate, confidence ellipses are generated based on non-parametric bootstrap (see [Figure 1](#f1){ref-type="fig"}).

![Confidence ellipse controlling for baseline utility.](hrbopenres-3-14145-g0000){#f1}

Examining these confidence ellipses, the shapes suggest that there exists significant variation in the incremental QALY than incremental cost. We can also conclude that at a 95% confidence level we are certain that the two programs will cost more but are less certain about incremental QALYs, particularly for the SIW group.

CEAC is generated to show how the probability that interventions will be cost effective as the decision-makers willingness-to-pay is increased (see [Figure 2](#f2){ref-type="fig"}). The ICERs beyond which the interventions become more likely to be cost effectiveness are €8190.28/QALY (SIW) and €6423.53/QALY (SIF). This also illustrates that SIF has a higher certainty of being cost-effective.

![Cost-effectiveness acceptability curve (CEAC) for cost per QALY analysis.](hrbopenres-3-14145-g0001){#f2}

At the commonly cited Spanish healthcare decision threshold of €45,000/QALY, the probability that SIW and SIF program being cost-effective was estimated to be P(ICER ~SIW~\<45,000/QALY)=0.7983 and P(ICER ~SIF~\<45,000/QALY)=0.9777, respectively.

Discussion
==========

This study extends beyond a definitive intervention trial with a clinically significant finding and presents within-trial cost-effectiveness analysis of two strategies for benzodiazepine cessation. The incremental cost effectiveness ratios suggest that both forms of interventions may represent value for money as they fall below explicitly cited decision-makers willingness-to-pay threshold ^[@ref-27]^. This study presents findings that suggest that benzodiazepine cessation may be likely to improve individuals overall generic health state.

GP training on managing long-term benzodiazepine cessation is associated with health benefit to patients. Many benzodiazepines are available in Spain and there is no simple way to examine whether the level of potential health gain may be directly associated with withdrawal from products however comparison to usual care find a small but significant incremental cost that appears justified by the expected benefit in each intervention group.

The perspective adopted was that of the healthcare payer (the Spanish Ministry of Health) and the calculation of total cost is based on intervention training costs, GP time and costs of benzodiazepine prescribed. The base-case does not extrapolate a model to indicate the adverse event or risk associated with long-term benzodiazepine use (e.g. falls, fractures, cognitive impairment or premature death). Such extrapolation could augment health-related quality of life (or costs to healthcare) and hypothetically alter ICERs. However, as the cost of intervention justifies health gain, the approach adopted is already justified and, in the absence of a comprehensive measure of resource use, model-based augmentation would require assumptions and may simply raise more questions than answers.

Conversion of HADS score onto associated EQ5D utility was used to provide a means to estimate incremental QALYs. This approach has some limitation. Firstly, Brazier *et al* indicate that the relationship between the EQ-5D and HADS differed across the severity scale, where the concordance between the measures was higher at the less severe end of the scale. Secondly, health state utilities are based on the UK tariff. Finally, the use of HADS scores bases the estimate of generic health solely on changes in anxiety and depression and overlooks other potential domains of generic health (e.g. EQ5D illicit QALYs based on mobility, self-care, usual activities, pain/discomfort and anxiety/depression). In the absence of a preference-weighted measure of generic health (such as EQ5D), this provides an imperfect solution to estimate QALYs.

Nevertheless, analyses based on the currently available information are supportive of a wider implementation of GP training for benzodiazepine cessation in Spain. There does remain a level of uncertainty in the estimated results, as well as limitations in the costs and outcomes utilised and a healthcare decision-maker may alternatively commission further research. The confidence ellipse provides support that there is value in additional information, as it would suggest that the true ICER is most likely to lie in the top right quadrant of the cost effectiveness plane suggesting any further investment (either towards implementation or additional research) will likely represent value for money to the Spanish Ministry of Health.

Data availability
=================

Underlying data
---------------

Zenodo: Cost-effectiveness of brief structured interventions to discontinue long-term benzodiazepine use: an economic analysis alongside a randomised controlled trial, <http://doi.org/10.5281/zenodo.3823846> ^[@ref-34]^.

Extended data
-------------

Zenodo: Supplemental 1: Full list of all benzodiazepine unit costs. Cost-effectiveness of brief structured interventions to discontinue long-term benzodiazepine use: an economic analysis alongside a randomised controlled trial, <https://doi.org/10.5281/zenodo.3835494> ^[@ref-32]^.

Zenodo: Supplemental 2: Costs associated with providing training workshops. Cost-effectiveness of brief structured interventions to discontinue long-term benzodiazepine use: an economic analysis alongside a randomised controlled trial <https://doi.org/10.5281/zenodo.3835506> ^[@ref-33]^.

Data are available under the terms of the [Creative Commons Attribution 4.0 International license](https://creativecommons.org/licenses/by/4.0/legalcode) (CC-BY 4.0).

Notes
=====

^a^Average Exchange Rate: GBP/EURO (2012-13): 0.8141; GBP/USD (2012-13): 0.6325 \[Sources: <http://www.hmrc.gov.uk/exrate/exchangerates-1213.pdf>\].
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Version 1

In this paper, the authors conduct a within-trial economic evaluation of brief interventions to discontinue long-term benzodiazepines use in the primary care setting in Spain. Specifically, they performed an incremental cost-effectiveness analysis of structured interviews with or without follow-up vs. usual care and find that both interventions are cost-effective, with ICERs well under the Spanish reimbursement threshold in both cases.

This is a particularly important topic and evidence is scarce regarding cost-effectiveness in this area. Long-term benzodiazepines use is a public health problem in most developing countries and studies are needed to show value for money of discontinuation strategies. This study therefore makes a valuable contribution to the literature.

The paper is methodologically sound and follows best practice guidelines in economic evaluation. It is well structured, and the analytical steps and assumptions are transparent. I have however a few comments and suggestions for clarification/possible improvement.

The abstract needs improvement in terms of style and content. Key information is lacking, especially the details on participants (GPs are mentioned, but brief details on patients included are needed, i.e. age range, definition of long-term use, etc.). Also, check consistency regarding direct (?) costs of long-term benzodiazepines use (figures in the abstract and in the text are not consistent). More generally, the paper would require some editing (e.g. check consistency of tense).

One important aspect is the definition of costs of benzodiazepines use, which is limited to direct drug costs in the paper, and more generally the scope of costs included. I would recommend clarifying the following statement (especially the last part) in the "Resource use and associated unit costs" section: "However, we restrict our consideration of cost to consider whether the health gains within the trial period justify the cost of the cessation programs plus subsequent benzodiazepine use". Also it is not fully clear whether GP cost is simply the unit cost of a GP visit multiplied by number of visits, or if broader costs were taken into account (including patient time costs) -- there is conflicting information about this in the text. In addition, was the cost of training limited to trainer time or also included opportunity cost for trainees? Finally, the authors explain that estimating the benefits of benzo discontinuation in terms of avoided costs related to adverse events is challenging. This is true but they can be quite confident that their ICERs are conservative and this could be more emphasised in the text.

In terms of outcomes, mapping is used from HADS to QALYs to derive utility scores. Given the limitations of this approach (that are clearly stated), it could be useful to show results in terms of cost per HADS score change (cost-effectiveness) in addition to cost per QALY (cost-utility), and perhaps other expression of value such as cost per successful discontinuation (needs more details on how this was measured in the trial)?
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